Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Aug 23;10(1):84.
doi: 10.1186/s13244-019-0771-1.

Diagnostic value of alternative techniques to gadolinium-based contrast agents in MR neuroimaging-a comprehensive overview

Anna Falk Delgado  1   2 , Danielle Van Westen  3 , Markus Nilsson  3 , Linda Knutsson  4   5 , Pia C Sundgren  3   6 , Elna-Marie Larsson  7 , Alberto Falk Delgado  7
Affiliations
Review

Diagnostic value of alternative techniques to gadolinium-based contrast agents in MR neuroimaging-a comprehensive overview

Anna Falk Delgado et al. Insights Imaging. .

Abstract

Gadolinium-based contrast agents (GBCAs) increase lesion detection and improve disease characterization for many cerebral pathologies investigated with MRI. These agents, introduced in the late 1980s, are in wide use today. However, some non-ionic linear GBCAs have been associated with the development of nephrogenic systemic fibrosis in patients with kidney failure. Gadolinium deposition has also been found in deep brain structures, although it is of unclear clinical relevance. Hence, new guidelines from the International Society for Magnetic Resonance in Medicine advocate cautious use of GBCA in clinical and research practice. Some linear GBCAs were restricted from use by the European Medicines Agency (EMA) in 2017.This review focuses on non-contrast-enhanced MRI techniques that can serve as alternatives for the use of GBCAs. Clinical studies on the diagnostic performance of non-contrast-enhanced as well as contrast-enhanced MRI methods, both well established and newly proposed, were included. Advantages and disadvantages together with the diagnostic performance of each method are detailed. Non-contrast-enhanced MRIs discussed in this review are arterial spin labeling (ASL), time of flight (TOF), phase contrast (PC), diffusion-weighted imaging (DWI), magnetic resonance spectroscopy (MRS), susceptibility weighted imaging (SWI), and amide proton transfer (APT) imaging.Ten common diseases were identified for which studies reported comparisons of non-contrast-enhanced and contrast-enhanced MRI. These specific diseases include primary brain tumors, metastases, abscess, multiple sclerosis, and vascular conditions such as aneurysm, arteriovenous malformation, arteriovenous fistula, intracranial carotid artery occlusive disease, hemorrhagic, and ischemic stroke.In general, non-contrast-enhanced techniques showed comparable diagnostic performance to contrast-enhanced MRI for specific diagnostic questions. However, some diagnoses still require contrast-enhanced imaging for a complete examination.

Keywords: Area under curve; Brain; Diagnostic performance; Gadolinium; Non-contrast-enhanced.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

References

    1. Runge VM, Clanton JA, Price AC, Wehr CJ, Herzer WA, Partain CL, et al. The use of Gd DTPA as a perfusion agent and marker of blood-brain barrier disruption. Magn Reson Imaging. 1985;3:43–55. doi: 10.1016/0730-725X(85)90008-6. - DOI - PubMed
    1. EMA (2017) EMA’s final opinion confirms restrictions on use of linear gadolinium agents in body scans. Available via www.ema.europa.eu/documents/press-release/emas-final-opinion-confirmsres.... Accessed on 30 Nov 2018.
    1. Wang Y, Alkasab TK, Narin O, Nazarian RM, Kaewlai R, Kay J, et al. Incidence of nephrogenic systemic fibrosis after adoption of restrictive gadolinium-based contrast agent guidelines. Radiology. 2011;260:105–111. doi: 10.1148/radiol.11102340. - DOI - PubMed
    1. Bennett CL, Qureshi ZP, Sartor AO, Norris LB, Murday A, Xirasagar S, et al. Gadolinium-induced nephrogenic systemic fibrosis: the rise and fall of an iatrogenic disease. Clin Kidney J. 2012;5:82–88. doi: 10.1093/ckj/sfr172. - DOI - PMC - PubMed
    1. Gulani V, Calamante F, Shellock FG, Kanal E, Reeder SB. Gadolinium deposition in the brain: summary of evidence and recommendations. Lancet Neurol. 2017;16:564–570. doi: 10.1016/S1474-4422(17)30158-8. - DOI - PubMed